DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA455748
Title:
Phase I/II Trial of 13-Cis Retinoic Acid, Alpha Interferon, Taxotere, and Estramustine (R.I.T.E.) for the Treatment of Hormone Refractory Prostate Cancer
Descriptive Note:
Annual rept. 15 Feb 2005-15 Jan 2006
Corporate Author:
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY NEW BRUNSWICK
Report Date:
2006-02-01
Pagination or Media Count:
6.0
Abstract:
Advanced prostate cancer is only temporarily controlled with androgen ablation therapy. In order to overcome tumor resistance we developed a epithelial cell line model to dissect out important mechanisms of resistance such as mutations in p53 and bcl-2 overexpression. In an attempt to sensitize these cells to paclitaxel TAX we found that 13-cis retinoic acid and alpha interferon CRAIFN was capable of overcoming bcl-2 mediated resistance and reduced the expression of bcl-2 in human prostate cancer cells. We hypothesized that drugs which could overcome bcl-2 mediated resistance would improve chemotherapy response or duration of response in the clinic. We then translated these results to the clinic in a series of clinical trials. Recently our phase II study with ORAlFNITAX was accepted as a National trial and is ongoing in the Eastern Cooperative Oncology Group. Given recent studies demonstrating that the combination of estramustine and docetaxel ET has increased response against HRPC in the clinic but limited median duration of response and our studies of CRAIFN in the laboratory and clinic we hypothesized that CRAIFN will improve the response rate or duration of response of ET in patients with HRPC. We will treat patients with HRPC with R.I.T.E. therapy in a phase I and II trial.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
